Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8221 to 8235 of 8314 results

  1. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  2. NICE recommends 'game changing' histology independent cancer drug

    Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).

  3. NICE recommends first treatment for rare blood disorder

    People with a rare blood disorder have access to a new treatment following draft guidance from NICE.

  4. Avelumab not recommended as a maintenance treatment of urothelial cancer

    NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.

  5. NICE signs up to join the GetReal Institute

    NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.

  6. Three treatments for COVID-19 recommended in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.

  7. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  8. The key to effective shared decision making is to involve people in meaningful conversations about their choices

    "Tell me and I forget. Teach me and I remember. Involve me and I learn." Benjamin Franklin.

  9. More people with rare genetic disorder eligible for nusinersen

    Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.

  10. Public consultation on updates to health technology evaluations manual

    A public consultation marking the first update to NICE's health technology evaluations manual is now open.

  11. Evidence Evusheld is effective in protecting vulnerable adults against variants lacking, as NICE announces new rapid update process for COVID-19 medicines

    NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.

  12. Hundreds of children with type 2 diabetes to be offered choice of two life changing technologies

    Children with type 2 diabetes who currently manage their condition with the stressful task of finger prick testing several times a day could be offered a choice between two ‘life changing’ technologies to virtually automate the process.

  13. NICE recommends genetic test to prevent newborn babies going deaf

    A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.

  14. Draft guidance recommends healthcare professionals ask people about gambling

    Health professionals should ask people about gambling if they attend a health check or GP appointment with a mental health problem, in a similar way to how people are asked about their smoking and alcohol consumption, according to new draft guidance.

  15. Supporting innovation: clear approval pathways and evidence standards for AI-driven digital health technologies

    Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.